

AWARD NUMBER: W81XWH-19-1-0474

TITLE: Development of remission-inducing therapy for TSC tumors

PRINCIPAL INVESTIGATOR: Jane Yu

CONTRACTING ORGANIZATION: University of Cincinnati, Cincinnati, OH

REPORT DATE: August 2020

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Development Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

*Form Approved*  
*OMB No. 0704-0188*

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE</b> August 2020			<b>2. REPORT TYPE</b> Annual		<b>3. DATES COVERED</b> 15Jul2019-14Jul2020	
<b>4. TITLE AND SUBTITLE</b> Development of remission-inducing therapy for TSC tumors					<b>5a. CONTRACT NUMBER</b> W81XWH-19-1-0474	
					<b>5b. GRANT NUMBER</b> W81XWH-18-TSCRP-EHDA	
					<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b> Jane Yu  E-Mail: jane.yu@uc.edu					<b>5d. PROJECT NUMBER</b>	
					<b>5e. TASK NUMBER</b>	
					<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> University of Cincinnati, Goodman Drive, P.O. Box 210222, Cincinnati, Ohio, 45221-0222					<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012					<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
					<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited						
<b>13. SUPPLEMENTARY NOTES</b>						
<b>14. ABSTRACT</b>  Tuberous sclerosis complex (TSC) is a rare genetic disease that causes benign tumors to grow in many different organs of the body. Although TSC tumors are not metastatic, these tumors can still cause problems, some critical, when the growth is located in vital organs such as the brain, kidney, and lung. Currently, there is no cure for TSC and treatment is largely devoted to surgical removal of tumors. Sometimes drugs such as rapamycin or related drugs are used to keep tumors from growing. Unfortunately, rapamycin only stops the tumor growth, does not make the tumors go away, and tumors enlarge further as soon as rapamycin is discontinued. In addition, long-term treatment can lead to side effects, such as diabetes, and resistance. In other words, TSC is an incurable lifelong disease, and the current treatments available only stop disease progression. They are not a cure. It is imperative to develop a new therapeutic approach that can only eliminate tumor rather just block growth but also do so without major side effects.						
<b>15. SUBJECT TERMS</b> None listed.						
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b>	<b>19a. NAME OF RESPONSIBLE PERSON</b>	
<b>a. REPORT</b>	<b>b. ABSTRACT</b>	<b>c. THIS PAGE</b>			<b>19b. TELEPHONE NUMBER</b> (include area code)	
Unclassified	Unclassified	Unclassified	Unclassified	12		

## TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Accomplishments	4
4. Impact	5
5. Changes/Problems	6
6. Products	7
7. Participants & Other Collaborating Organizations	7
8. Special Reporting Requirements	7
9. Appendices	7

**1. Introduction.** Tuberous sclerosis complex (TSC) is a rare genetic disease that causes benign tumors to grow in many different organs of the body. Although TSC tumors are not metastatic, these tumors can still cause problems, some critical, when the growth is located in vital organs such as the brain, kidney, and lung. Currently, there is no cure for TSC and treatment is largely devoted to surgical removal of tumors. Sometimes drugs such as rapamycin or related drugs are used to keep tumors from growing. Unfortunately, rapamycin only stops the tumor growth, does not make the tumors go away, and tumors enlarge further as soon as rapamycin is discontinued. In addition, long-term treatment can lead to side effects, such as diabetes, and resistance. In other words, TSC is an incurable lifelong disease, and the current treatments available only stop disease progression. They are not a cure. It is imperative to develop a new therapeutic approach that can only eliminate tumor rather just block growth but also do so without major side effects.

## **2. Keywords**

Tuberous Sclerosis Complex (TSC), mTORC1 inhibitors, rapamycin, RNAseq

## **3. Accomplishments**

**Aim 1. Determine the molecular basis for rapamycin-induced survival of TSC2-deficient cells in vivo.** Our hypothesis is that prolonged rapamycin treatment leads to resistance by triggering pro-survival genes that confer survival.

**Major Task 1.** Establish xenograft tumors of 621-101 in response to rapamycin.

Subtask 1: We have established xenograft tumors at 4 tumor stages (Tumor-1 [vehicle], 2 [shrinking], 3 [refractory], & 4 [regrowth]) (**Figure 1**).

Subtask 2: We have harvested xenograft tumors at 4 tumor stages and isolated RNA.

**Major Task 2:** Identify gene expression signature responsible for tumor refractoriness.

Subtask 1: Perform two-step gene selection to identify genes responsible for resistance and regrowth by comparing with **ELT3 xenograft data**.

We have previously employed RNAseq on ELT3 tumor samples. We collaborated with Dr. Medvedovic to perform data mining to identify genes responsible for refractoriness. Step-1: distinguish gene signatures associated with rapamycin-induced regrowth by comparing transcriptome of Tumor-3 with Tumor-2. Step-2: eliminate common genes to cytostatic tumor-2. Step-3: perform secondary pathway analysis to identify pro-

survival and cell death pathways (**Figure 2**). Among the significant differentially expression genes, we identified the epidermal growth factor like domain multiple 6 (*EGFL6*), a secreted protein classically known to promote endothelial cell angiogenesis during wound healing and in cancer growth. *EGFL6* expression was increased by 119.4-fold in rapamycin refractory tumor compared to rapamycin sensitive tumor. We further validated RNA-seq findings using Real-time PCR analyses. The transcript level of *EGFL6* is significantly elevated in rapamycin refractory ELT3 tumors relative to that in rapamycin sensitive tumors (**Figure 3**).

Moreover, we have discovered an Mitogen-activated protein kinase (MAPK)-evoked positive feedback loop that dampens the efficacy of mTORC1 inhibition. Mechanistically, mTORC1 inhibition increased MEK1-dependent activation of MAPK in TSC-deficient cells. Pharmacological inhibition of MAPK abrogated this feedback loop activation. Importantly, the combinatorial inhibition of mTORC1 and MAPK induces the death of TSC2-deficient cells. Our results provide a rationale for dual targeting of mTORC1 and MAPK pathways in TSC and other mTORC1 hyperactive neoplasm. This work was published in August 2020 (Listed in the Product section and included in Appendix section).

- 4. Impact.** Tuberous Sclerosis Complex (TSC) is an autosomal dominant disorder with multi-system manifestations including development of benign neoplasms in the brain, heart, lung, and kidneys. TSC is caused by TSC1 or TSC2 gene mutations, resulting in constitutive activation of the mechanistic target of rapamycin complex 1 (mTORC1). mTOR is a protein kinase that regulates gene transcription, protein synthesis, ribosome biogenesis, autophagy, cell metabolism, and cell growth. Recent clinical trials in TSC demonstrate that mTORC1 inhibitors (rapamycin or everolimus) decrease the volume of TSC tumors, subependymal giant cell astrocytomas and renal angiomyolipomas, and stabilize pulmonary function decline. However, tumors regrow and symptoms resume when treatment is discontinued. This cytostatic rather than a cytotoxic effect accounts for need for continuous therapy. Furthermore, despite the efficacy in most patients, a subset of TSC patients experience rapamycin resistance and progress. Therefore, there is a critical need to identify the molecular drivers of distinct therapeutic responses in TSC. We will utilize two innovative, state-of-the-art technologies: RNASeq to identify rapamycin-induced gene expression in xenograft tumors of rat ELT3 and patient angiomyolipoma-derived cells, and non-invasive imaging for evidence of tumor growth and cell death. Our proposal directly addresses the following FY18 focus areas:

1) Understanding phenotypic heterogeneity in TSC. Our proposal aims to identify phenotypic heterogeneity of TSC by performing RNAseq gene expression analysis of TSC tumors under informative conditions; (1) no treatment control condition, (2) chronic rapamycin treated cytostatic condition, 3) rapamycin-resistant refractory condition, and 4) rapamycin cessation. 2) Gaining a deeper knowledge of TSC signaling pathways and the cellular consequences of TSC deficiency: Our study primarily focuses on identifying the signaling pathways that, under long-term rapamycin treatment, protect TSC tumor cells from cell death induction. We will elucidate the molecular mechanisms by which cells acquire rapamycin-resistance. The s RNAseq gene analysis is powerful and informative, more so than any other gene analysis, with regard elucidation of cell signaling analysis. This technique can clearly detail the cellular responses of tumor cells in each response stage. Therefore, we can identify distinct and extraordinarily relevant signal transduction pathways in response to the treatment in all of the cells in a tumor, but not the possibility of the tumor response to the treatment. 3) Improving TSC disease models. Our study will investigate the biology of TSC tumor cells under rapamycin treatment. Our approach using RNA-seq can provide us information to understand how rapamycin treatment affects the heterogeneous cell populations and their response to the treatment in the TSC tumors. These studies will refine an existing rodent model of TSC. 4) Facilitating therapeutics and clinical trials research. The effect of mTOR inhibitors on TSC tumors in these experiments has been consistently cytostatic rather than cytotoxic, tumors typically regrow upon the cessation of treatment, and resistance can evolve. This proposal aims to identify novel signaling pathways that account for these responses to inhibitor therapy by targeted RNAseq analysis of the discrete tumor response. These basic studies will ultimately lead to transformative clinical trials with new combination therapies with rapamycin and/or its analogs. In summary, understanding the mechanism of mTOR inhibitor-induced cytostasis and resistance will lead to improved therapy for patients with TSC and other neoplasms.

**5. Changes/Problems.** This award began in October 2019. We started xenograft tumor experiments proposed in Aim 1 in October 2019. Tumors were harvested and RNA was isolated. Research operation was shutdown at University of Cincinnati due to the COVID-19 pandemic outbreak in March - May 2020. Our experiments were halted for three months. Consequently, we were unable to continue some wet bench studies. Because Dr. Medvedovic could continue bioinformatic analysis in remote settings, we started to work on Major Task 2 focusing on analyzing previous ELT3 xenograft datasets for comparison work. We

really appreciate that this award would be extended by one year enabling us to complete the proposed studies.

## 6. Products.

Yiyang Lu, Erik Y. Zhang, Jie Liu, Jane J. Yu. Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex. *Orphanet J Rare Dis*. 2020 Aug 17;15(1):209. PMID: 32807195 PMCID: PMC7433150

## 7. Participants & Other Collaborating Organizations

Jane Yu, Erik Zhang, Yiyang Lu, Naim Mahi, Mario Medvedovic


## 8. Special Reporting Requirements. N/A

## 9. Appendices.

### 9a. Figure 1. Development of xenograft tumors of 621-101 cells in response to rapamycin treatment.


TSC2-null angiomyolipoma-derived 621-101 cells were subcutaneously inoculated into NSG mice. Mice bearing xenograft tumors were treated with rapamycin (2 mg/kg/day, i.p.) for four weeks (Week 1 to 5). Tumor regrowth was observed for two additional weeks (Week 6-7) upon rapamycin withdrawal. Tumor volume was measured using digital calipers and normalized to those prior to rapamycin treatment. Tumor Stage 1=rapamycin shrinking tumor; Tumor Stage 2=rapamycin sensitive shrinking tumor; Tumor stage 3=rapamycin growing tumor; and Tumor Stage 4=rapamycin withdrawn growing tumor.

## Xenograft tumors of 621-101 cells




**9b. Figure 2. RNAseq analysis of ELT3 xenograft tumors in response to prolonged rapamycin treatment.** RNA samples were isolated from xenograft tumors of Tsc2-null ELT3 cells at Tumor Stage-2 rapamycin sensitive and Tumor Stage-3 rapamycin refractory. RNAseq analysis was performed. The Heatmap shows representative genes differentially expressed and enriched in signaling pathways in response to prolonged rapamycin treatment.

## RNAseq analysis of ELT3 xenograft tumors



**9c. Figure 3. EGFL6 expression is prominent in xenograft tumors of ELT3 in response to prolonged rapamycin treatment.** (A) RNAseq was performed in xenograft tumors of ELT3 cells. Volcano plot shows significant gene (red,  $P$  value  $< 0.01$ ) between rapamycin-sensitive tumors vs rapamycin-refractory tumors. Red dots represent genes whose expression was significantly altered ( $P < 0.01$ ), and black dots represent genes without significant changes. (B) Immunohistochemistry staining of xenograft tumors from vehicle, rapamycin-sensitive and rapamycin-refractory groups. Tumor tissues were stained with antibodies against PCNA, phospho-MAPK (T202/Y204), and EGFL6. Representative images are shown.



### 9d. SOW and highlight progress

Specific Aim 1: Determine the molecular basis for rapamycin-induced survival of TSC2-deficient cells in vivo.	Timeline (Months)	Site 1 (PI)
Obtain HRPO and ACURO approval	1-3	Dr. Yu
<b>Major Task 1:</b> Establish xenograft tumors of 621-101 in response to rapamycin.		
<p><b>Subtask 1:</b> Collect xenograft tumors at 4 tumor stages (Tumor-1 [vehicle], 2 [shrinking], 3 [refractory], &amp; 4 [regrowth]) and characterize these tumors for mTORC1 suppression and growth. (n= 8 per stage, for a total of 32 animals).  Step-1: subcutaneously inoculate NOD/SCID mice with 621-101-luciferase expressing cells and monitor xenograft tumor development using bioluminescent imaging.  Step-2: When tumors become well established based on stable bioluminescent imaging, drug treatment will be given 5 times/week:  1) rapamycin (2 mg/kg/day, i.p.), and  2) vehicle (0.5% hydroxypropylmethylcellulose, 0.2% Tween 80 in diH2O).  Step-3: collect xenograft tumors at 4 tumor stages as described above.  Step-4: validate each tumor stage for rapamycin responsiveness using immunohistochemistry of phospho-S6 (S235/236).</p>	4-6	Dr. Yu
<b>Subtask 2:</b> Harvest tumors, isolate RNA, and perform RNAseq.	7-9	UC Core
Subtask 3: Perform RNAseq analysis, data processing, and data mining in collaboration with Dr. Medvedovic.	10-15	Drs. Yu and Medvedovic
<b>Major Task 2:</b> Identify gene expression signature responsible for tumor refractoriness	Months	
<b>Subtask 1:</b> Perform two-step gene selection to identify genes responsible for resistance and regrowth by comparing with ELT3 xenograft data.	16-17	Dr. Yu

<p>Subtask 2: Identify gene sets responsible for rapamycin-resistance and/or tumor refractoriness.</p> <p><b>Step-1: distinguish gene signatures associated with rapamycin-induced regrowth by comparing transcriptome of Tumor-3 with Tumor-2.</b></p> <p>Step-2: eliminate common genes to cytostatic tumor-2.</p> <p>Step-3: perform secondary pathway analysis to identify pro-survival and cell death pathways.</p>	18-19	Dr. Yu
<p><b>Subtask 3: Validate gene expression using real-time quantitative PCR</b> and immunoblot analysis with RNAs and proteins from four tumor stages, as biological triplicates, in each condition.</p>	20-24	Dr. Yu
<p><i>Milestone #1: Manuscript preparation on rapamycin-induced gene signatures responsible for tumor refractoriness in TSC.</i></p>		
<p><b>Specific Aim 2: Determine the effect of pro-survival signaling blockade on rapamycin resistant TSC2-deficient cells in vivo.</b></p>	Months	
<p><b>Obtain HRPO and ACURO approval</b></p>	1-3	Dr. Yu
<p><b>Major Task 3: Develop mesenchymal tumor xenograft model of patient-associated renal angiomyolipoma-derived cells carrying bi-allelic TSC2 mutations</b></p>		
<p>Subtask 1: Establish tumors for testing agents in xenograft models. (n=8 per group, for a total of 32 animals)</p>	4-6	Dr. Yu
<p>Subtask 2: When tumors become well established based on stable bioluminescent imaging, drug treatment will be given 5 times/week for four weeks:</p> <p>3) rapamycin (2 mg/kg/day, i.p.)</p> <p>4) trametinib (2 mg/kg/day, oral gavage)</p> <p>5) rapamycin (2 mg/kg/day) plus trametinib (2 mg/kg/day), and</p> <p>6) vehicle (0.5% hydroxypropylmethylcellulose, 0.2% Tween 80 in diH2O).</p>		
<p>Subtask 2: Test drug effects on tumor progression using bioluminescent imaging.</p>	7-12	Dr. Yu
<p><b>Major Task 4: Testing the effect of pharmacologic suppression of MAPK activation using MEK1/2 inhibitor trametinib, singly or in combination with the mTORC1 inhibitor rapamycin, on the progression of 621-101 cells using non-invasive bioluminescent imaging technology.</b></p>	Months	
<p>Subtask 1: Using animals from Major Task 3, test drug treatment effects on 621-101 tumor growth using non-invasive bioluminescent imaging. Efficacy of downregulation of mTORC1 and MEK1/2 will be examined using immunoblotting analyses and immunohistochemistry of phospho-S6 and phospho-MAPK</p>	13-15	Dr. Yu
<p>Subtask 2: Test drug treatment effects on tumor regrowth after drug discontinuation.</p>	16-18	Dr. Yu
<p><b>Major Task 5: Testing the effect of molecular depletion of pro-survival genes identified in Aim 1 on the progression of 621-101 xenograft tumors</b></p>	Months	
<p>Subtask 1: Establish stable knockdown of gene of interest in 621-101 cells using shRNA. Stable cell lines will be injected subcutaneously into NOD/SCID mice. (n=8 per shRNA group, two independent shRNAs/gene of interest, two control shRNAs, for a total of 32 animals per gene of interest)</p>	19-21	Dr. Yu

<p>Subtask 2: Examine the effect of depletion of pro-survival genes identified in Aim 1 on the progression of xenograft tumors of 621-101 cells.</p> <p>Step-1: deplete gene “X” using two independent shRNA-X or shRNA-control vector in 621-101 cells. Stable clones will be selected, validated for gene depletion using qPCR and immunoblotting analysis.</p> <p>Step-2: shRNA-X and shRNA-control cells will be subcutaneously inoculated into NOD/SCID mice (n=8 per group, for a total of 32 animals per gene of interest).</p> <p>Step-3: tumor development and progression will be monitored using bioluminescent imaging very two weeks. Bioluminescent intensity in xenograft tumors shRNA-X mice will be compared with shRNA-control mice.</p>	22-24	Dr. Yu
<p>Subtask 3: To assess tumor cell viability, perform noninvasive fluorescent imaging to detect cell proliferation and apoptosis, in vivo and ex vivo. Fluorescence intensity in xenograft tumors from drug-treated mice will be compared with vehicle treatment. Mouse plasma will be prepared and analyzed for levels of rapamycin.</p>	22-24	Dr. Yu
<p><i>Milestone #2: Manuscript preparation on identification of novel pro- survival regulators induced by rapamycin treatment in TSC</i></p>		

### 9e. Publication

Yiyang Lu, Erik Zhang, Jie Liu and **Jane J. Yu**. Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex. ***Orphanet J Rare Dis***. 2020 Aug 17;15(1):209. PMID: 32807195